myNEO

Ottergemsesteenweg-Zuid 808 B511

9000 Gent

BE

myNEO

Foundation date

01/12/2018

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

myNEO is a distinguished Belgian biotech powerhouse dedicated to pioneering breakthrough immunotherapies tailored to target diverse tumor profiles. myNEO's discovery platform leverages immuno-genomic datasets to identify tumor alterations and unveil promising and largely untapped immunotherapeutic targets. In vivo studies underscore myNEO's prowess in identifying effective tumor targets. myNEO is now advancing development of its proprietary 'camyotopes', a class of long non-coding RNAs that shows selective translation in tumor tissue and a robust immunogenic multi-targeted response against the tumor. The lead program CAMYO-01 will validate the MOA of the camyotopes in a CRC phase I/II trial, while simultaneously expanding the development pipeline to other indications.

Upcoming events

Latest news

  • Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

    Wednesday March 27th 2024

  • InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline

    Tuesday March 26th 2024

  • Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

    Monday March 25th 2024